Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

2016; Elsevier BV; Volume: 43; Linguagem: Inglês

10.1016/j.leukres.2016.02.005

ISSN

1873-5835

Autores

J.B. Fraison, A. Mékinian, Éric Grignano, Jean‐Emmanuel Kahn, Jean‐Benoît Arlet, Olivier Decaux, Guillaume Denis, Anne-Laure Buchdahl, Mohamed Omouri, G. Maigné, Achille Aouba, Nathalie Léon, S. Berthier, É. Liozon, Sophie Park, Claude Gardin, Olivier Lortholary, Julien Rossignol, Pierre Fenaux, O. Fain, Thorsten Braun,

Tópico(s)

Blood disorders and treatments

Resumo

This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n = 11), both unfavorable (n = 2), but AID improved while MDS/CMML worsened (n = 8) and vice versa (n = 1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings.

Referência(s)